Aspirin is currently recommended from 12 weeks gestation until the birth of the baby for women with one high, or two moderate risk factors for pre-eclampsia, to reduce the risk of developing the condition. There is evidence to suggest aspirin use in pregnancy potentially reduces the risk of preterm birth and small for gestational age or fetal growth restricted babies. For women with recurrent pregnancy loss associated with anti-phospholipid syndrome, aspirin is recommended in combination with heparin. In this review, we discuss the history of aspirin use and its application to improving pregnancy outcomes. We also highlight the current evidence surrounding aspirin use in pregnancy and explore avenues for further research.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Obstetrics, Gynaecology and Reproductive Medicine
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Pre-eclampsia: pathophysiology and clinical implications.BMJ. 2019; 366: l2381
- Current management of recurrent pregnancy loss.Obstet Gynecol. 2022; 24: 260-271
- Antiplatelet agents for preventing pre-eclampsia and its complications.Cochrane Database Syst Rev. 2019; : CD004659
- Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial.Lancet. 2020; 395: 285-293
- Pre-eclampsia prevention using routine versus screening test-indicated aspirin in low-risk women.Hypertension. 2018; 72: 1391-1396
Published online: January 14, 2023
© 2023 Elsevier Ltd. All rights reserved.